Home › Funds › Vestal Point Capital, LP › NKTR
Vestal Point Capital, LP position in NKTR
NEKTAR THERAPEUTICS · Health Care
Vestal Point Capital, LP reported holding 510,000 shares of NKTR (NEKTAR THERAPEUTICS) in its Q3 2026 13F filing — a position valued at US$30.9M, representing 0.80% of its reported portfolio and ranking #23 among its reported holdings. Vestal Point Capital, LP has disclosed NKTR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
Last updated: 2026-11-17 · Source: SEC EDGAR Form 13F-HR
How Vestal Point Capital, LP's NKTR position evolved
Vestal Point Capital, LP first disclosed a stake in NKTR in Q1 2026 at 285,000 shares (US$20.5M). The position peaked in Q2 2026 at 1,000,000 shares, worth US$69.8M. Across 3 filings, Vestal Point Capital, LP increased the stake 1 time(s), trimmed it 1 time(s) and left it unchanged 0 time(s). The most recent filing (Q3 2026) shows 510,000 shares valued at US$30.9M — a reduction of -490,000 shares quarter over quarter.. Notable position changes include a 251% increase in Q2 2026 (shares fell 13% over the following quarter), a 49% trim in Q3 2026 (shares fell 40% over the following quarter).
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q1 2026 | 285.00K | $20.51M | New |
| Q2 2026 | 1.00M | $69.81M | Add |
| Q3 2026 | 510.00K | $30.88M | Reduce |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About NKTR and 13F data
NKTR (NEKTAR THERAPEUTICS) is a Health Care company. 50 other funds we track also report a position in NKTR — the largest reported positions include Two Seas Capital LP (US$202.6M), BVF INC/IL (US$129.2M), Prosight Management, LP (US$47.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding NKTR
- Two Seas Capital LP 3.35M sh · $202.58M · Q3 2026
- BVF INC/IL 2.13M sh · $129.20M · Q3 2026
- Prosight Management, LP 785.00K sh · $47.53M · Q3 2026
- ARMISTICE CAPITAL, LLC 700.00K sh · $42.38M · Q3 2026
- BRAIDWELL LP 443.59K sh · $26.86M · Q3 2026
- ORBIMED ADVISORS LLC 384.52K sh · $23.28M · Q3 2026
- DAFNA Capital Management LLC 323.38K sh · $19.58M · Q3 2026
- 22NW, LP 281.12K sh · $17.02M · Q3 2026
- ADAR1 Capital Management, LLC 258.18K sh · $15.63M · Q3 2026
- SEVEN GRAND MANAGERS, LLC 240.00K sh · $14.53M · Q3 2026
- Bronte Capital Management Pty Ltd. 202.06K sh · $12.23M · Q3 2026
- GREAT POINT PARTNERS LLC 175.00K sh · $10.60M · Q3 2026
More on Vestal Point Capital, LP
FAQ
How long has Vestal Point Capital, LP held NKTR?
Vestal Point Capital, LP has disclosed NKTR holdings in 3 of the last 3 reported quarters, going back to Q1 2026.
What is Vestal Point Capital, LP's current position in NKTR?
As of Q3 2026, Vestal Point Capital, LP holds 510.00K shares of NKTR (NEKTAR THERAPEUTICS), valued at $30.88M, representing 0.80% of its reported portfolio and ranking #23.
Has Vestal Point Capital, LP been buying or selling NKTR?
In the latest 13F filing (Q3 2026), Vestal Point Capital, LP reduced its position in NKTR. The position peaked in Q2 2026 at 1.00M shares.
Which other funds hold NKTR?
Other major institutional holders of NKTR include Two Seas Capital LP, BVF INC/IL, Prosight Management, LP, among 50 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.